サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1787191

mRNA治療薬開発・製造受託機関の世界市場

mRNA Therapeutics Contract Development & Manufacturing Organization

出版日
ページ情報
英文 166 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=149.53円
mRNA治療薬開発・製造受託機関の世界市場
出版日: 2025年08月08日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 166 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のmRNA治療薬開発・製造受託機関の市場規模は、2030年までに90億米ドルに達する見込み

世界のmRNA治療薬開発・製造受託機関の市場規模は、2024年に50億米ドルと推定され、2024～2030年の分析期間中にCAGR10.3%で成長し、2030年には90億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである感染症適応は、CAGR8.8%を記録し、分析期間終了時には50億米ドルに達すると予測されます。代謝・遺伝性疾患セグメントの成長率は、分析期間中CAGR12.8%と推定されます。

米国市場は13億米ドルと推定、中国はCAGR9.5%で成長予測

米国のmRNA治療薬開発・製造受託機関市場は、2024年には13億米ドルに達すると推定されます。世界第2位の経済大国である中国は、2030年までに14億米ドルの市場規模に達すると予測され、分析期間2024～2030年のCAGRは9.5%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ8.9%と8.5%と予測されています。欧州では、ドイツがCAGR8.3%で成長すると予測されています。

mRNA治療薬開発・製造受託機関の世界市場：主要動向と促進要因の概要

なぜmRNA治療薬CDMOの需要が増加しているのか？

mRNAベースの医薬品やワクチンの台頭により、mRNA治療薬に特化した開発・製造受託機関（CDMO）の需要が劇的に高まっています。バイオテクノロジー企業や製薬会社は研究開発に重点を置いているため、mRNAの大規模生産に必要なインフラを持たない企業が多く、専門のCDMOへのニーズが高まっています。これらの組織は、原料調達、試験管内転写（IVT）、精製、脂質ナノ粒子（LNP）製剤化など、必要不可欠なサービスを提供しています。特にCOVID-19パンデミックの際に実証されたmRNA治療薬の急速なスケーラビリティは、世界のワクチンと医薬品の供給を確保する上でCDMOの重要性を強めています。さらに、mRNAの用途がワクチンだけでなく、個別化医療、がん免疫療法、希少疾患治療へと拡大したことで、製造の複雑さが増し、専門家であるCDMOへのアウトソーシングが戦略的に必要となっています。バイオテクノロジー産業が革新を続ける中、CDMOは臨床開発と商業生産のギャップを埋める重要な存在となり、mRNA治療薬が効率的かつコスト効率よく市場に投入されることを保証しています。

どのような革新がmRNA治療薬の製造を変革しているのか？

技術の進歩はmRNA治療薬製造の効率とスケーラビリティを大幅に改善し、医薬品製造におけるCDMOの役割を強化しています。最も重要な技術革新の1つは、自動化されたクローズドシステムIVTプロセスの開発であり、これによりコンタミネーションリスクが軽減され、バッチの一貫性が向上しました。また、脂質ナノ粒子（LNP）カプセル化技術の改良により、mRNAの安定性と標的への送達が改善され、最適な治療効果が得られるようになりました。AIを活用したmRNA配列設計の最適化と予測モデリングにより、CDMOは生産パラメーターを改良し、無駄を省いて収率を向上させることができるようになりました。さらに、シングルユースのバイオプロセシングシステムの進歩により、CDMOはコストと交差汚染のリスクを最小限に抑えながら、柔軟性を高めることができるようになりました。連続製造とリアルタイムの品質管理システムは、製造ワークフローをさらに合理化し、臨床および商業規模の製造における納期の短縮を可能にしています。mRNAベースの治療法が自己増幅型RNA（saRNA）や環状RNA（circRNA）へと進化する中、CDMOは革新的なmRNAプラットフォームに対する需要の高まりに応えるため、最先端の製造技術に投資しています。

規制とサプライチェーンの要因は、mRNA治療薬CDMO市場をどのように形成しているか？

規制要件の複雑化と世界のサプライチェーン力学が、mRNAに特化したCDMOの経営戦略を形成しています。FDAやEMAなどの規制機関はmRNA治療薬に関する厳格なガイドラインを制定しており、CDMOはGMPに準拠した施設を維持し、厳格な品質管理プロトコルを実施する必要があります。個別化医療の進化に伴い、特にカスタマイズされた製剤を必要とするmRNAベースのがんワクチンや遺伝子治療薬では、規制状況の承認経路がさらに複雑化しています。ヌクレオチド、キャッピング試薬、脂質を含む必須原材料のグローバルサプライチェーンも混乱に直面しており、CDMOは地域製造ハブや垂直統合戦略に投資し、中断のない生産を確保する必要に迫られています。さらに、CDMOとバイオテクノロジー企業との連携により、サプライチェーンの強靭性が強化され、新たなヘルスケア課題への迅速な対応が可能になりました。デジタル製造プラットフォームとブロックチェーンベースの追跡システムの採用により、トレーサビリティとコンプライアンスがさらに向上し、mRNAベースの医薬品の生産と流通における透明性が確保されています。

mRNA治療薬CDMO市場の主な成長促進要因は？

mRNA治療薬CDMO市場の成長は、mRNA医薬品開発への投資の増加、バイオ医薬品パイプラインの拡大、スケーラブルな製造ソリューションへのニーズの高まりなど、いくつかの要因によってもたらされます。mRNAベースのCOVID-19ワクチンの成功により、次世代mRNA治療薬への資金調達が加速し、感染症、腫瘍、代謝性疾患を対象とした臨床試験の急増につながっています。製薬会社は、運用コストを削減し、市場投入までの時間を短縮するため、mRNA生産をCDMOに委託するケースが増えています。自己増幅型RNAやサーキュラーRNAといった次世代RNA技術の出現により、CDMOの専門能力に対する需要はさらに高まっています。さらに、モジュール式やシングルユースのバイオプロセシングシステムの採用が進んでいるため、CDMOは柔軟でコスト効率の高い製造ソリューションを提供できるようになりました。政府やバイオテクノロジー企業がパンデミックへの備えや個別化医療を優先する中、mRNA治療薬CDMOの役割は拡大し、革新的なmRNAベースの治療が効率的かつ大規模に世界市場に到達することが期待されています。

セグメント

適応症（感染症適応、代謝・遺伝子疾患、心血管・脳血管疾患）、用途（ウイルスワクチン、タンパク質代替療法、がん免疫療法）、最終用途（バイオテクノロジー企業、政府・学術研究機関、製薬企業）

調査対象企業の例

  • AGC Biologics
  • Aldevron
  • ARCALIS, Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CordenPharma International
  • Curia Global, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Laboratorios Farmaceuticos Rovi, S.A.
  • Lonza Group
  • Merck KGaA
  • Moderna, Inc.
  • Rentschler Biopharma SE
  • Samsung Biologics
  • ST Pharm
  • Thermo Fisher Scientific
  • TriLink BioTechnologies
  • Vernal Biosciences
  • WuXi AppTec

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

一般的に行われているLLMや業界特化型SLMへのクエリに頼るのではなく、私たちは世界中のドメイン専門家によって精選されたコンテンツを集約したリポジトリを構築しました。その中には、動画の文字起こし、ブログ、検索エンジンを用いた調査、さらには膨大な企業データ、製品・サービス情報、市場データが含まれています。

関税影響係数

私たちは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP32237

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market to Reach US$9.0 Billion by 2030

The global market for mRNA Therapeutics Contract Development & Manufacturing Organization estimated at US$5.0 Billion in the year 2024, is expected to reach US$9.0 Billion by 2030, growing at a CAGR of 10.3% over the analysis period 2024-2030. Infectious Diseases Indication, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$5.0 Billion by the end of the analysis period. Growth in the Metabolic & Genetic Diseases Indication segment is estimated at 12.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.3 Billion While China is Forecast to Grow at 9.5% CAGR

The mRNA Therapeutics Contract Development & Manufacturing Organization market in the U.S. is estimated at US$1.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.4 Billion by the year 2030 trailing a CAGR of 9.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.9% and 8.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.3% CAGR.

Global mRNA Therapeutics Contract Development & Manufacturing Organization Market - Key Trends & Drivers Summarized

Why Is the Demand for mRNA Therapeutics CDMOs Increasing?

The rise of mRNA-based drugs and vaccines has dramatically increased the demand for contract development and manufacturing organizations (CDMOs) specializing in mRNA therapeutics. As biotechnology and pharmaceutical companies focus on research and development, many lack the infrastructure required for large-scale mRNA production, driving the need for specialized CDMOs. These organizations provide essential services, including raw material sourcing, in vitro transcription (IVT), purification, and lipid nanoparticle (LNP) formulation. The rapid scalability of mRNA therapeutics, particularly demonstrated during the COVID-19 pandemic, has reinforced the importance of CDMOs in ensuring global vaccine and drug supply. Additionally, the expansion of mRNA applications beyond vaccines into personalized medicine, cancer immunotherapy, and rare disease treatments has increased the complexity of production, making outsourcing to expert CDMOs a strategic necessity. As the biotech industry continues to innovate, CDMOs have become crucial in bridging the gap between clinical development and commercial manufacturing, ensuring that mRNA therapeutics reach the market efficiently and cost-effectively.

What Innovations Are Transforming the Manufacturing of mRNA Therapeutics?

Technological advancements have significantly improved the efficiency and scalability of mRNA therapeutics manufacturing, enhancing the role of CDMOs in drug production. One of the most critical innovations is the development of automated and closed-system IVT processes, which reduce contamination risks and improve batch consistency. The refinement of lipid nanoparticle (LNP) encapsulation technology has also improved mRNA stability and targeted delivery, ensuring optimal therapeutic effects. AI-driven optimization of mRNA sequence design and predictive modeling have enabled CDMOs to refine production parameters, reducing waste and improving yield. Additionally, advancements in single-use bioprocessing systems have allowed CDMOs to enhance flexibility while minimizing costs and cross-contamination risks. Continuous manufacturing and real-time quality control systems have further streamlined production workflows, enabling faster turnaround times for clinical and commercial-scale manufacturing. As mRNA-based therapies evolve to include self-amplifying RNA (saRNA) and circular RNA (circRNA), CDMOs are investing in cutting-edge production techniques to meet the growing demand for innovative mRNA platforms.

How Are Regulatory and Supply Chain Factors Shaping the CDMO Market for mRNA Therapeutics?

The increasing complexity of regulatory requirements and global supply chain dynamics is shaping the operational strategies of mRNA-focused CDMOs. Regulatory agencies such as the FDA and EMA have established stringent guidelines for mRNA therapeutics, requiring CDMOs to maintain GMP-compliant facilities and implement rigorous quality control protocols. The evolving landscape of personalized medicine has further complicated regulatory approval pathways, particularly for mRNA-based cancer vaccines and gene therapies that require customized formulations. The global supply chain for essential raw materials, including nucleotides, capping reagents, and lipids, has also faced disruptions, prompting CDMOs to invest in regional manufacturing hubs and vertical integration strategies to ensure uninterrupted production. Additionally, collaborations between CDMOs and biotech firms have strengthened supply chain resilience, enabling rapid response to emerging healthcare challenges. The adoption of digital manufacturing platforms and blockchain-based tracking systems has further improved traceability and compliance, ensuring transparency in the production and distribution of mRNA-based drugs.

What Are the Key Growth Drivers in the mRNA Therapeutics CDMO Market?

The growth in the mRNA therapeutics CDMO market is driven by several factors, including the increasing investment in mRNA drug development, expanding biopharmaceutical pipelines, and the rising need for scalable manufacturing solutions. The success of mRNA-based COVID-19 vaccines has accelerated funding for next-generation mRNA therapies, leading to a surge in clinical trials for infectious diseases, oncology, and metabolic disorders. Pharmaceutical companies are increasingly outsourcing mRNA production to CDMOs to reduce operational costs and accelerate time-to-market. The emergence of next-generation RNA technologies, such as self-amplifying RNA and circular RNA, has further increased demand for specialized CDMO capabilities. Additionally, the growing adoption of modular and single-use bioprocessing systems has enabled CDMOs to offer flexible, cost-effective manufacturing solutions. As governments and biotech firms prioritize pandemic preparedness and personalized medicine, the role of mRNA therapeutics CDMOs is expected to expand, ensuring that innovative mRNA-based treatments reach global markets efficiently and at scale.

SCOPE OF STUDY:

The report analyzes the mRNA Therapeutics Contract Development & Manufacturing Organization market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Indication (Infectious Diseases Indication, Metabolic & Genetic Diseases Indication, Cardiovascular & Cerebrovascular Diseases Indication); Application (Viral Vaccines Application, Protein Replacement Therapies Application, Cancer Immunotherapies Application); End-Use (Biotech Companies End-Use, Government & Academic Research Institutes End-Use, Pharmaceutical Companies End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 34 Featured) -

  • AGC Biologics
  • Aldevron
  • ARCALIS, Inc.
  • BioNTech SE
  • Catalent, Inc.
  • CordenPharma International
  • Curia Global, Inc.
  • FUJIFILM Diosynth Biotechnologies
  • Laboratorios Farmaceuticos Rovi, S.A.
  • Lonza Group
  • Merck KGaA
  • Moderna, Inc.
  • Rentschler Biopharma SE
  • Samsung Biologics
  • ST Pharm
  • Thermo Fisher Scientific
  • TriLink BioTechnologies
  • Vernal Biosciences
  • WuXi AppTec

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • mRNA Therapeutics Contract Development & Manufacturing Organization - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Surge in mRNA-based Therapeutics Drives Significant Demand for Specialized CDMO Services
    • Increasing Investment in mRNA Vaccine and Therapeutic Development Expands the Addressable Market for CDMOs
    • Growth in Pharmaceutical Outsourcing for mRNA Production Strengthens the Business Case for CDMO Partnerships
    • Technological Advancements in mRNA Manufacturing Processes Propel Growth in CDMO Offerings
    • Rising Need for Scalable and Flexible Manufacturing Solutions Drives the Adoption of CDMO Services in mRNA Production
    • Regulatory Support for mRNA Therapeutics and Vaccines Expands Opportunities for CDMOs in the Market
    • The Emergence of mRNA-based Cancer Therapies Generates Long-term Growth for CDMO Services in Oncology
    • Increasing Complexity of mRNA Synthesis Drives Demand for Advanced Expertise and Technology in CDMO Partnerships
    • Expansion of Global Clinical Trials for mRNA-based Drugs Strengthens Market Opportunities for CDMO Providers
    • The Growing Role of CDMOs in the Production of mRNA Vaccines for Emerging Infectious Diseases Expands Market Reach
    • Increasing Focus on Speed and Efficiency in mRNA Drug Development Accelerates Demand for Specialized CDMO Services
    • The Rise of Personalized Medicine and Targeted Therapies Boosts Demand for Custom CDMO Solutions in mRNA Production
    • Increasing Collaboration Between Biopharma Companies and CDMOs Expands Market Growth Potential for mRNA Therapeutics
    • The Growth of Public and Private Investments in mRNA Technology Strengthens the Financial Case for CDMO Expansion
    • The Need for High-Quality and GMP-compliant Manufacturing Drives Adoption of Leading CDMO Providers for mRNA Production
    • Regulatory Challenges in mRNA Therapeutic Manufacturing Drive Innovation in CDMO Capabilities and Standards
    • The Continued Success of COVID-19 Vaccines Strengthens Long-term Demand for mRNA Therapeutics and CDMO Services
    • The Shift Towards Modular and Automated Manufacturing Solutions Promotes Growth and Efficiency in mRNA CDMOs
    • The Increasing Demand for Global Supply Chain Optimization in mRNA Production Expands CDMO Opportunities
    • Growing Competitive Landscape in mRNA Therapeutics Drives Demand for Specialized and Reliable CDMO Partnerships
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World mRNA Therapeutics Contract Development & Manufacturing Organization Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Infectious Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 5: World 6-Year Perspective for Infectious Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Metabolic & Genetic Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 7: World 6-Year Perspective for Metabolic & Genetic Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cardiovascular & Cerebrovascular Diseases Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World 6-Year Perspective for Cardiovascular & Cerebrovascular Diseases Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Viral Vaccines Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 11: World 6-Year Perspective for Viral Vaccines Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Protein Replacement Therapies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 13: World 6-Year Perspective for Protein Replacement Therapies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Cancer Immunotherapies Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World 6-Year Perspective for Cancer Immunotherapies Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 17: World 6-Year Perspective for Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Government & Academic Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 19: World 6-Year Perspective for Government & Academic Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Pharmaceutical Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World 6-Year Perspective for Pharmaceutical Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 22: USA Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 23: USA 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 25: USA 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • CANADA
    • TABLE 28: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 29: Canada 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 31: Canada 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • JAPAN
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 34: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 35: Japan 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 37: Japan 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • CHINA
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 40: China Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 41: China 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 43: China 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • EUROPE
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 46: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 47: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 49: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 52: Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 53: Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • FRANCE
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 54: France Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 55: France 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 58: France Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 59: France 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • GERMANY
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 60: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 61: Germany 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 64: Germany Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 65: Germany 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • ITALY
    • TABLE 66: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 67: Italy 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 70: Italy Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 71: Italy 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • UNITED KINGDOM
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 72: UK Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 73: UK 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 76: UK Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 77: UK 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • REST OF EUROPE
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 82: Rest of Europe Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 83: Rest of Europe 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • ASIA-PACIFIC
    • mRNA Therapeutics Contract Development & Manufacturing Organization Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 88: Asia-Pacific Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 89: Asia-Pacific 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030
  • REST OF WORLD
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 91: Rest of World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Indication - Percentage Breakdown of Value Sales for Infectious Diseases Indication, Metabolic & Genetic Diseases Indication and Cardiovascular & Cerebrovascular Diseases Indication for the Years 2025 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by Application - Percentage Breakdown of Value Sales for Viral Vaccines Application, Protein Replacement Therapies Application and Cancer Immunotherapies Application for the Years 2025 & 2030
    • TABLE 94: Rest of World Recent Past, Current & Future Analysis for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 95: Rest of World 6-Year Perspective for mRNA Therapeutics Contract Development & Manufacturing Organization by End-Use - Percentage Breakdown of Value Sales for Biotech Companies End-Use, Government & Academic Research Institutes End-Use and Pharmaceutical Companies End-Use for the Years 2025 & 2030

IV. COMPETITION